Ionis Pharmaceuticals, Inc.
56.02USD
-0.6900 (-1.22%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 587.4M | 787.6M | 705.1M | 943.7M | 913.4M | 1.4B |
| Q1 | 141.9M | 130.5M | 119.5M | 131.6M | 246.1M | — |
| Q2 | 133.8M | 188.4M | 225.3M | 452.0M | 267.9M | — |
| Q3 | 159.8M | 144.2M | 133.8M | 156.7M | 184.3M | — |
| Q4 | 151.9M | 324.5M | 226.6M | 203.3M | 231.3M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -1.90 | -2.56 | -3.04 | -2.38 | -2.72 | -1.08 |
| Q1 | -.460 | -.870 | -.980 | -.930 | -.560 | — |
| Q2 | -.740 | -.600 | -.450 | .700 | -.690 | — |
| Q3 | -.330 | -1.03 | -.950 | -.800 | -.916 | — |
| Q4 | -.370 |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -.060 |
| -.660 |
| -1.41 |
| -.889 |
| — |